Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland.
利用健康技術評估制定管理訪問協議以促進愛爾蘭的藥物報銷。
Appl Health Econ Health Policy 2024-08-12
Use of insulin pumps and closed-loop systems among people living with diabetes: A narrative review of clinical and cost-effectiveness to enable access to technology and meet the needs of payers.
糖尿病患者使用胰島素泵和封閉迴路系統:臨床和成本效益的敘述性回顧,以促進技術的使用並滿足支付者的需求。
Diabetes Obes Metab 2023-06-06
A methodology to assess the population size and estimate the needed resources for new licensed medications by combining clinical and administrative databases: The example of glycated haemoglobin in type 2 diabetes.
結合臨床和行政資料庫評估人口規模並估計新授權藥物所需資源的方法:以第二型糖尿病中糖化血紅蛋白為例。
Pharmacoepidemiol Drug Saf 2023-10-10
Automated versus manual prior authorization for diabetes mellitus drugs: A retrospective study from Israel.
以色列糖尿病藥物的自動化與手動事先授權:一項回顧性研究。
Digit Health 2023-10-04
Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations.
醫療保險病患的比較真實世界證據研究的可用性:對於美國醫療保險與醫療補助服務藥物價格談判的影響。
J Comp Eff Res 2024-04-23
Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
擴大抗生素、疫苗和診斷工具的研發和取得,以應對抗微生物藥物抗性。
Lancet 2024-05-26
Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program.
在抗肥胖藥物中平衡創新與負擔能力:另類體重維持計畫的角色。
Health Aff Sch 2024-06-03
RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16.
RWE準備好用於報銷了嗎?與健康技術評估相關的真實世界證據發展綜述:第16部分。
J Comp Eff Res 2024-07-05
How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes.
新藥品採用如何影響美國健康系統在替代支付模式下的醫療費用核算:一個經濟模型,評估 sotagliflozin 對心臟衰竭和糖尿病患者的影響。
J Manag Care Spec Pharm 2024-07-11